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Abstract
Background: There are inconsistent findings on the role of hyperuricemia as an independent risk factor for chronic kidney
disease (CKD). Hypertension has been implicated as a factor influencing the association between serum uric acid and CKD.
In this population-based study we investigated the association between serum uric acid and decline in renal function and
tested whether hypertension moderates this association.
Methods: We included 2601 subjects aged 55 years and over from the Rotterdam Study. Serum uric acid and estimated
glomerular filtration rate (eGFR) were assessed at baseline. After average 6.5 years of follow-up, second eGFR was assessed. CKD
was defined as eGFR,60 ml/min/1.73 m2. All associations were corrected for socio-demographic and cardiovascular factors.
Results: Each unit (mg/dL) increase in serum uric acid was associated with 0.19 ml/min per 1.73 m2 faster annual decline in
eGFR. While the association between serum uric acid and incidence of CKD was not significant in our study population
(Hazard Ratio: 1.12, 95% confidence interval [CI]: 0.98–1.28), incorporating our results in a meta-analysis with eleven
published studies revealed a significant association (Relative Risk: 1.18, 95%CI: 1.15–1.22). In the stratified analyses, we
observed that the associations of serum uric acid with eGFR decline and incident CKD were stronger in hypertensive
subjects (P for interaction = 0.046 and 0.024, respectively).
Conclusions: Our findings suggest that hyperuricemia is independently associated with a decline in renal function. Stronger
association in hypertensive individuals may indicate that hypertension mediates the association between serum uric acid
and CKD.
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Background
The incidence of chronic kidney disease (CKD) is steadily
increasing [1]. Affected individuals have high rates of cardiovas-
cular morbidity and mortality and often require costly treatments
such as dialysis and kidney transplantation [2]. Identifying novel
risk factors for CKD may improve preventative programs that
would eventually decrease the burden caused by this disease [3].
One of the recently proposed risk factors for CKD is
hyperuricemia [4]. Although elevated serum uric acid is associated
with CKD, it is not clear whether hyperuricemia plays a
detrimental role in developing CKD or if it merely is a
consequence of lower glomerular filtration rate prior to CKD
[5]. To this end, different prospective studies investigated the
association between serum uric acid and incident CKD [4,6–18].
However, these studies showed inconsistent findings [19–21].
Furthermore, a growing body of evidence supports a role for uric
acid in developing hypertension, a well-established risk factor for
CKD [22,23]. We hypothesize that hypertension might mediate
the effect of uric acid on renal function. If so, the association
between serum uric acid and CKD should be stronger in
hypertensive individuals.
In this study we investigated the association of serum uric acid
with decline in estimated glomerular filtration rate (eGFR) and
incident CKD in the Rotterdam Study, a prospective cohort study
of individuals 55 years and older. Moreover, we performed a
meta-analysis to provide a reliable estimate of the effect of serum
uric acid on risk of CKD. Finally, we studied whether this
association differs in hypertensive and normotensive individuals.
Methods
Population
The Rotterdam Study is a population-based cohort study,
including 7,983 participants living in Ommoord, a district of
Rotterdam, The Netherlands. All participants aged 55 and over,
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were invited to this study (n= 10,275). The Rotterdam Study
started in the early 1990s and periodical examinations were
performed every 3 to 5 years. In addition, participants were
continuously followed for vital status, obtaining information
regularly from the municipal health authorities in the Rotterdam
area. The study was approved by the Medical Ethics Committee of
the Erasmus Medical Center and written informed consent was
obtained from all participants [24,25].
Uric acid
Serum uric acid was measured once at baseline. Values of
serum uric acid were obtained from baseline non-fasting blood
samples which were centrifuged for 10 minutes at 3000 rotations
per minute and subsequently stored at 220uC for one week. Uric
acid activity was ascertained with Kone Diagnostica reagent kit
and Kone autoanalyzer [26]. In order to check the calibration, for
every 10 samples, 3 control samples were included. In each run
(100 samples), if the average values of the control samples were not
within 2.5% of the true value, the run was repeated. Calibration
was also done on day-by-day variation, which had to be within 5%
[27].
eGFR decline and incident CKD
Serum creatinine was measured twice; first at baseline visit and
second at follow up visit. At baseline visit serum creatinine was
determined using non-kinetic alkaline picrate (Jaffe´) method. At
follow up visit serum creatinine was determined using an
enzymatic assay method [28]. In order to calibrate, we aligned
the mean values of serum creatinine with serum creatinine values
of the participants of the Third National Health and Nutrition
Examination Survey (NHANES III) in different gender and age
groups (,60, 60–69, $70). Measurements were done for 5280
individuals at baseline (1989–1993) and 3867 individuals at the
follow up visit (1997–1999). eGFR was calculated using the
simplified Modification of Diet in Renal Disease (MDRD)
equation which is recommended by the National Kidney
Foundation [28]. CKD was defined as eGFR,60 ml/min per
1.73 m2. To calculate the annual eGFR decline, we first
subtracted the eGFR estimates of the follow up examination from
the eGFR estimates at baseline and then divided by the time
between the two visits. These two examinations were on average
6.5 years apart. Incident cases were defined among the individuals
free of CKD at baseline (eGFR.60 ml/min per 1.73 m2), who
had a decline in eGFR to less than 60 ml/min per 1.73 m2
between the two periodical examinations. To estimate the
censoring date of the cases, we assumed a linear decrease in
eGFR. Given this assumption, the date that each case had passed
the eGFR threshold of 60 ml/min per 1.73 m2 was taken as the
censoring date and it was used to calculate the follow up time for
incident cases. For controls, the time spent between the two
examinations was used as the follow up time.
Covariates
Body mass index was calculated by dividing weight in kilograms
by height in meters squared. Serum total cholesterol and high
density lipoprotein cholesterol levels was determined using an
automated enzymatic method. Information on smoking and
alcohol consumption was acquired from the questionnaires.
Participants were asked for the average daily consumption of
alcohol. Coronary heart disease was considered as experiencing
myocardial infarction or coronary revascularization procedures.
Diabetes mellitus was defined as the use of blood glucose lowering
drugs or a random non-fasting glucose above 11.1 mmol/l.
Hypertension was defined as systolic blood pressure $140 mmHg
or diastolic blood pressure $90 mmHg or use of blood pressure
lowering medication with hypertension as the indication. Medi-
cation use information is based on home interview. Data for all the
covariates were obtained once at baseline.
Population for analysis
As depicted in Figure 1, from 7983 participants at baseline,
5139 individuals had available data at baseline. We further
excluded 164 participants using antigout medications (allopurinol,
probenecid, benzbromarone, and colchicine). Among 4975
subjects 1132 died during the 6.5 years of follow-up time, 62
participants were not able to participate in the follow up visit, 947
subjects did not participate in the follow up visit and 233 did not
have second serum creatinine measurements. This resulted in a
sample of 2601 participants for the longitudinal analyses on eGFR
decline. Furthermore, we excluded subjects with baseline CKD
(n= 196) for the analyses on the incidence of CKD.
Statistical analysis
A linear regression model was used to evaluate the association
between serum uric acid (mg/dL) and eGFR decline. The Cox
proportional hazard model was applied to calculate the hazard
ratio (HR) for the association between serum uric acid and
incidence of CKD. All analyses were adjusted for age, sex and
baseline eGFR. In a multivariate analysis, we additionally adjusted
for potential confounders including systolic blood pressure,
diabetes mellitus, body mass index, high density lipoprotein,
alcohol consumption, smoking, total cholesterol, coronary heart
disease, and use of diuretics, beta blockers, calcium channel
blockers, and ACE inhibitors. Analysis was further done in
subgroups of hypertensive and normotensive individuals. Interac-
tion was assessed, by adding an interaction term in the regression
model. The interaction term was the product of the interacting
factor and serum uric acid. R version 2.13.0 was used to calibrate
creatinine values at baseline and follow up. All the other analyses
were carried out using SPSS 17.0.2 for windows.
Meta-analysis
We searched for studies published in MEDLINE (PubMed),
EMBASE and Web of Science using the common key words
related to incidence of chronic kidney disease and serum uric acid
including ‘‘renal disease’’ or ‘‘renal insufficiency’’ or ‘‘kidney
disease’’ and ‘‘blood urate’’ or ‘‘serum uric acid’’ or ‘‘hyperuri-
cemia’’. We restricted the language of the search to English.
Population-based studies which evaluated the association between
serum uric acid and incidence of CKD were included in our meta-
analysis. Some of the eligible studies had used different outcome
definitions and measurements of serum uric acid. Therefore, we
contacted nine authors to obtain results consistent with our
definitions and adjustments. Authors were asked to adjust the
analysis for the following variables: age, sex, smoking, alcohol
consumption, body mass index, diabetes, hypertension, total
cholesterol, baseline kidney function, and proteinuria. From 12
studies, 6 studies provided HR and 6 studies used odds ratio (OR)
to report the effect size. Since the incidence of CKD is relatively
low [29], we accepted OR as a proxy for HR and combined them
in the meta-analysis. Data used for the meta analysis is available in
supplementary document (Table S1).The heterogeneity assump-
tion was investigated using a commonly used statistical method,
namely the I-square statistic [30]. Publication bias was evaluated
using the Egger’s test [31]. The statistical analyses were performed
using the ‘‘meta’’ package of the statistical software R, version
2.13.0. Moreover, we tested the publication bias using STATA
version 10.
Uric Acid and Chronic Kidney Disease
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e76827
Results
As depicted in Figure 1 among 4975 individuals at risk of
developing CKD at baseline, 2374 subjects either died or were lost
to follow up during 6.5 years of follow up. Comparing them with
the population included in the analysis, they were significantly
older and had higher C-reactive protein level, systolic blood
pressure, and serum uric acid. They also had lower eGFR, alcohol
consumption, total cholesterol and body mass index. Finally, they
were more likely to use antihypertensive medication and to have
diabetes mellitus, CKD, and coronary heart disease (Table S2).
Baseline characteristics
The study population had an average age of 70.4 years, serum
uric acid level of 5.38 mg/dL, and eGFR of 77.15 ml/min per
1.73 m2. As shown in Table 1, subjects in the higher quartiles of
serum uric acid were older and more likely to be male, diabetic,
alcohol drinker, and former smoker. They had a significantly
higher body mass index, systolic and diastolic blood pressure, C-
reactive protein level, history of coronary heart disease and
prevalence of antihypertensive medications use. In addition, they
had lower levels of eGFR and HDL cholesterol.
Serum uric acid and eGFR decline
Average annual eGFR decline was 0.92 ml/min per 1.73 m2
(SD=2.21) for all participants. For each unit increase in serum
uric acid, the annual eGFR decline was higher by 0.19 ml/min
per 1.73 m2 (95% confidence interval [CI]: 0.13–0.26) in the age
and sex adjusted model and 0.18 ml/min per 1.73 m2 (95%CI:
0.10–0.26) in the multivariate adjusted model (Table 2). We
repeated the analyses in subgroups of hypertensive and normo-
tensive participants. In both models, the association was stronger
in hypertensive subjects compared to normotensive subjects (P-
value for interaction= 0.020). Hypertensive participants in the
highest quartile of serum uric acid had 1.12 higher risk of annual
eGFR decline per one unit increase in serum uric acid compared
to those in the lowest quartile (Figure 2-A).
Serum uric acid and incidence of CKD
As shown in Table 3, serum uric acid was associated with
incident CKD in age and sex adjusted model (HR: 1.22; 95%CI:
1.10–1.35). After further adjusting for potential confounders, the
direction of the association remained the same; however, the
strength of the association attenuated and it was no longer
statistically significant (1.12; 95%CI: 0.98–1.28). We further
examined the association between serum uric acid and CKD
separately in hypertensive and normotensive participants. In both
models, the association was present in hypertensive subjects (HR:
1.29, 95%CI: 1.14–1.46) but absent in normotensive subjects (HR:
1.03, 95%CI: 0.85–1.24) (P-value for interaction= 0.030). Hyper-
tensive participants in the highest quartile of serum uric acid had
more than three times higher risk of developing CKD compared
with those in the lowest quartile (Figure 2-B). To further explore
whether other metabolic factors, including high density lipopro-
Figure 1. Population for analysis.
doi:10.1371/journal.pone.0076827.g001
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tein, diabetes, and waist circumference, could influence the
association of uric acid with incidence of CKD, we performed a
series of stratified analyses. These stratified analyses showed that
there was no statistical difference, in the association of serum uric
acid and incidence of CKD, between different groups of
participants (Figure S1).
Meta-analysis of serum uric acid and incidence of CKD
Figure 3 shows the flow diagram for inclusion of the relevant
studies in our meta-analysis [6,7,12,17,18,32–37]. We performed a
fixed effect model meta-analysis on 12 studies including 11
published studies and the current analysis from the Rotterdam
Study (Figure 4). The overall relative risk was 1.18 (95%CI: 1.15–
Table 1. Baseline characteristics of the participants in different quartiles of uric acid levels.
Uric Acid Quartiles (mg/dL*)
#4.5 4.5–5 5–6 .6 P for trend**
(n =1257) (n =1210) (n=1263) (n =1245)
Age, mean (SD{), y 69.1(8.9) 70.4(9.2) 70.4(9.0) 71.5(9.4) ,0.001
Men (%) 208 (16.5) 374(30.9) 586(46.4) 705(56.6) ,0.001
Smoking
Current (%) 312(24.8) 277(22.9) 313(24.8) 245(19.7) 0.001
Former (%) 366(29.1) 429(35.5) 529(41.9) 614(49.3)
Daily Alcohol Intake in drinkers, median
(Interquartile range), g/d
4.5(0.7–13.6) 5.0(1.0–14.8) 9.3(1.7–21.2) 11.2(2.5–27.9) ,0.001
Body mass index, mean (SD), kg/m2 25.2(3.4) 25.7(3.5) 26.6(3.6) 27.3(3.8) ,0.001
Waist circumference, mean (SD), cm 84.8(10.8) 87.7(10.3) 91.7(10.2) 94.8(10.5) ,0.001
Total cholesterol, mean (SD), mmol/L 6.6(1.2) 6.5(1.2) 6.6(1.3) 6.6(1.2) 0.472
HDL cholesterol, mean (SD), mmol/L 1.4(0.3) 1.3(0.3) 1.3(0.3) 1.2(0.3) ,0.001
C-reactive protein, median
(Interquartile range), mg/L
1.3(0.6–2.7) 1.8(0.9–3.4) 2.0(1.0–3.8) 2.5(1.2–4.6) ,0.001
Glomerular filtration rate, mean (SD), ml/min
per 1.73 m2
82.9(16.8) 78.3(15.4) 76.1(16.3) 71.1(18.2) ,0.001
Systolic blood pressure, mean (SD), mm Hg 137.3(22.2) 138.3(21.7) 139.3(21.5) 141.2(22.4) ,0.001
Diastolic blood pressure, mean (SD), mm Hg 72.6(11.5) 72.8(11.6) 73.4(11.6) 74.0(12.1) 0.091
Chronic kidney disease (%) 65(5.2) 116(9.6) 173(13.7) 331(26.6) ,0.001
Diabetes Mellitus (%) 136(10.9) 109(9.1) 125(9.9) 178(14.4) ,0.001
History of coronary heart disease (%) 88(7.1) 121(10.2) 193(15.4) 264(21.6) ,0.001
Diuretics (%) 101(8.0) 125(10.3) 189(15.0) 413(33.2) ,0.001
Calcium channel blockers (%) 52(4.1) 46(3.8) 75(5.9) 131(10.5) ,0.001
Beta-blockers (%) 103 (8.2) 134(11.1) 192(15.2) 293(23.5) ,0.001
ACE inhibitors (%) 41(3.3) 33(2.7) 61(4.8) 126(10.1) ,0.001
*To convert to SI unit multiply by 59.48.
**P-value adjusted for age and sex for continuous measure of uric acid.
{Standard Deviation.
doi:10.1371/journal.pone.0076827.t001
Table 2. The association between serum uric acid (mg/dL) and decline in estimated glomerular filtration rate (ml/min per 1.73 m2).
Minimally adjusted Model** Multivariate adjusted Model{
N Annual decline 95% CI* P-value N
Annual
decline 95% CI P-value
Total population 2601 0.19 0.13, 0.26 1.2610210 2312 0.18 0.10, 0.26 1.061025
Normotensive 1312 0.13 0.03, 0.23 0.008 1167 0.14 0.03, 0.25 0.014
Hypertensive 1275 0.24 0.14, 0.33 7.861029 1145 0.20 0.08, 0.31 0.001
P for interaction 0.020 0.046
*CI: confidence interval.
**Adjusted for age, sex, and baseline eGFR.
{Adjusted for age, sex, systolic blood pressure, body mass index, alcohol consumption, smoking, high density lipoprotein, diabetes mellitus, coronary heart disease, total
cholesterol, and the use of diuretics, beta blockers, calcium channel blockers, ACE inhibitors, and baseline eGFR.
doi:10.1371/journal.pone.0076827.t002
Uric Acid and Chronic Kidney Disease
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e76827
Figure 2. Association of serum uric acid with kidney function in normotensive and hypertensive subjects (A) Annual decline in
eGFR in relation to serum uric acid quartiles in hypertensive and normotensive participants. Analyses are adjusted for age, sex and
baseline eGFR. Quartiles are compared with participants in the first quartile of serum uric acid (,4.5 mg/dL) (B) Risk of incident CKD in relation to
quartiles of serum uric acid level in hypertensive and normotensive participants. Analyses are adjusted for sex, age and baseline eGFR. All odds ratios
are compared with participants in the first quartile of serum uric acid (,4.5 mg/dL).
doi:10.1371/journal.pone.0076827.g002
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1.22) for incidence of CKD per 1 mg/dL higher level of serum
uric acid. There was no evidence of publication bias (Egger’s test
P-value = 0.583) and test for heterogeneity resulted in moderate
estimates (I2 = 57.7% [19.7%–77.7%]).
Discussion
In this prospective cohort study, we found that high levels of
serum uric acid are associated with faster decline in eGFR and
increased incidence of CKD. Moreover, combining our finding
with 11 published population-based studies in a meta-analysis
suggested a role for serum uric acid as an independent predictor of
incident CKD. Finally, we observed that the association is more
pronounced in hypertensive subjects compared to normotensive
individuals.
A number of recent studies evaluated the relation between
serum uric acid and incidence of CKD [4,7–17,38]. In agreement
with our findings, some of them introduced high serum uric acid as
a risk factor for the development of CKD [4,6–13,17]. Weiner et
al. pooled data from Atherosclerosis Risk in Communities (ARIC)
study and Cardiovascular Health Study (CHS) and found an odds
ratio of 1.11 for CKD incidence per one unit (mg/dl) increase in
serum uric acid [13]. However, these findings were contradicted
with some other reports. A large cohort of 28,745 young
participants (age 20–49 years) in Taiwan showed a weak
correlation between serum uric acid and eGFR (Pearson
correlation=20.22) [20]. Moreover, Sturm et al. analyzed 227
patients with primary non-diabetic CKD and found that the
association between high serum uric acid and progression of CKD
disappeared after adjustment for potential confounders [21].
Given these inconsistencies, we performed a meta-analysis to
combine the results of published studies on serum uric acid and
incident CKD. Our meta-analysis, based on 12 studies including
the current study, confirmed the association between high serum
uric acid and CKD incidence. This finding is in accordance with
the results of trials that have shown a slower progression of CKD
after treatment with allopurinol [39,40].
We found evidence for moderate heterogeneity in the associ-
ation between serum uric acid and CKD in our meta-analysis.
One possible explanation is that potential intermediate factors are
not evenly distributed among these studies. Hypertension is one of
the factors that may play an important role in the association
between serum uric acid and CKD. The correlation between
serum uric acid and hypertension is well-documented [41,42] and
a large number of studies have reported linear and dose dependent
associations between serum uric acid and Blood pressure. In
current study we observed that the association between high
serum uric acid and CKD was stronger in hypertensive
individuals compared to normotensives. In agreement with this
finding, in the study of normotensive adults no association was
found between high serum uric acid and incidence of CKD [7].
These findings may offer an explanation for the heterogeneity
between studies and may provide evidence for possible role of
hypertension in mediating the association between high serum
uric acid and CKD.
Different explanations can be presented for our observation
regarding the association of serum uric acid with risk of CKD and
the role of hypertension. Uric acid can increase the risk of CKD
directly through inhibition of endothelial nitric oxide bioavailabil-
ity, activation of the renin-angiotensin system, and increase in
Table 3. The association between serum uric acid (mg/dL) and incidence of chronic kidney disease.
Minimally adjusted Model{ Multivariate adjusted Model{{
N(case) HR* 95% CI** P-value N(case) HR* 95% CI P-value
Total population 2405 (289) 1.22 1.10, 1.35 1.861022 2154 (249) 1.12 0.98, 1.28 0.079
Normotensive 1243 (112) 1.03 0.85, 1.24 0.747 1111(102) 0.96 0.78,1.19 0.758
Hypertensive 1149 (175) 1.29 1.14, 1.46 4.461023 1043(147) 1.23 1.04, 1.45 0.016
P for interaction 0.030 0.024
*HR: hazard ratio.
**CI: confidence interval.
{Adjusted for age, sex, and baseline eGFR.
{{Adjusted for age, sex, systolic blood pressure, body mass index, alcohol consumption, smoking, high density lipoprotein, diabetes mellitus, coronary heart disease,
total cholesterol, diuretics, beta blockers, calcium channel blockers, ACE inhibitors, and baseline eGFR.
doi:10.1371/journal.pone.0076827.t003
Figure 3. Flow diagram of studies through the different phases
of the meta-analysis.
doi:10.1371/journal.pone.0076827.g003
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renal microvascular damage [43,44]. Moreover, it is possible
that high serum uric acid leads to kidney damage through
conventional risk factors for CKD such as hypertension. It has
been shown that high serum uric acid increases the risk of
developing hypertension by enhancing salt sensitivity [23].
Another possible explanation might be that antihypertensive
medications such as diuretics increase serum uric acid level in
hypertensive individuals [45], and consequently elevated serum
uric acid may directly result in kidney damage [46]. In this study
we adjusted our analyses for different types of antihypertensive
medications including diuretics; therefore it is unlikely that the
associations were influenced by the medication use. We adjusted
the analyses for the use of any diuretic; however, we
acknowledge that different types of diuretics have differential
impact on serum uric acid concentrations.
Our study has several strengths. First, the Rotterdam Study is a
large population-based cohort study, which on one hand provides
sufficient statistical power to answer our research question and on
the other hand could be generalized to general population.
Second, we controlled for several potential confounders such as
different types of antihypertensive medications, and performed the
analyses separately in subgroups of hypertensives and normoten-
sives. Third, we performed a meta-analysis that provides a robust
estimate of the association. Different limitations of this study
should also be acknowledged. First, no data on albuminuria were
available, which is an important element in defining CKD.
However, CKD definition of eGFR,60 ml/min per 1.73 m2 is a
well-accepted definition in population-based research settings [47].
Second, 2374 participants were lost to follow up, mainly because
they died before the follow up visit. These subjects were older, had
lower eGFR, higher serum uric acid level, and more often had
hypertension and diabetes mellitus. Since subjects who dropped
out from our study during follow up period had higher uric acid
levels and were more likely to develop CKD, we may have
underestimated the association between serum uric acid and risk of
CKD.
Conclusion
We have demonstrated that serum uric acid is independently
associated with the risk of CKD. This association was significantly
stronger in hypertensive individuals. Future studies are needed to
test whether better monitoring or even lowering of serum uric acid
levels in hypertensive patients can slow down the progression of
CKD.
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